Mesothelioma Asbestos Cancer

The malignant mesothelioma is the rare shape of cancer which starts in mésothélium, a membrane which covers and protects the majority from the internal bodies from the body. The mésothélium is composed of two lawyers, one which surrounds the body itself, and the other which forms a bag surrounding it completely. A small quantity of liquid is normally produced between these two lawyers, lubricating the movement of the protected bodies. When the normal cells of mésothelium lose their control and are disseminated quickly, they produce a mesothelioma. The most common form of mesothelioma is the "pleural" mesothelioma. It occurs in the plèvre, the coating of the lungs. The other forms are the mesothelioma "péritonéal", reaching the peritoneum, coating of the abdominal cavity and the "pericardial" mesothelioma, of the pericardium, the coating of the heart.

The mesothelioma is almost always caused by the exposure to asbestos fibres. Many people were exposed there to the army; others by their occupation; and others still, secondarily, in contact with exposed workmen. Because of the latent state of cancer, it can appear only 20 to 50 years or more after exposure.

On the basis of information obtained from the Finnish Institute of professional health in Helsinki, the incidence of the mesothelioma in Western Europe is supposed to reach its peak between 2010 and 2020. Hereafter are the statistics on the currently available incidence by country.

Finland 75 (2002) 18 ; France 870 (2000) 18 ; Germany 1094 (2001) 16 ; Great Britain 1862 (2002) 39 ; Italy 1050 (2000) 21 ; Paysbas 389 (2000) 30 ; Norway 57 (2000) 16 ; Sweden 149 (2003) 20

Those which directly worked with asbestos or products of asbestos run the greatest risk to develop a mesothelioma, however, the mesothelioma was reported at certain individuals having had a tiny exposure. Among the high-risk trade of development of mesothelioma one finds: The iron carpenter (including shipbuilding) manufacturers of the chassis (including vehicles of the rail) Plumbers Fitters of gas Carpenters Hard-working Electricians of the building Plasterers Contractors Handymen Manufacturers out of steel Painters Sheet-iron merchants Welders

The following products commonly contained asbestos fluctuating rates. This list does not include them all and is only one source of general information. Moulded or preformed shielding used in the thermal insulation of pipes and boilers asbestos projected used like fire-protection in conduits, fire wall, panels, partitions, boards of soffit, ceiling panels and construction structural out of steel Panels of insulation used like fire-protection, thermal insulation, separations and led Stuffing of asbestos used like fire wall in the false ceilings rolled up Paperboard, paper and produced out of paper used for the electric insulation of material; the asbestos paper can also be used as fireproof reverse on the fiberboards of Produits wood of asbestos cement in sheets punts and undulated used to cover ceilings or walls; the products of cement were also used in the gutters, the pipelines water of rain and the water tanks the coatings with roofing texture (such Artex) Material of roof out of Carreau bitumen of floor out of vinyl or thermoplastic

Symptoms : The early symptoms of the mesothelioma are of nature nonspecific and can delay the diagnosis. In general, breathlessness, pain of chest and persistent cough are common symptoms of the pleural mesothelioma, but in certain case, they cannot be sufficiently serious only to push the patient with a medical consultation. Certain patients complain about pain of the scapula or the bottom of the back. These symptoms most of the time occur 2-3 month before a confirmed diagnosis. In the mesothelioma péritonéal, abdominal pain and swelling, nausea or vomiting, intestinal obstruction and loss of weight are the most common symptoms. In an important way, these symptoms are not particular mesothelioma and can thus be symptoms of other conditions. The evaluation by a qualified doctor is always recommended. Whereas the mesothelioma progresses, pleural overflowing (accumulation of fluid between the two pleural layers) occurs at 95 % of the patients, and it is this symptom which finally pleasing patients to consult their doctor. At the time of this visit, a thoracic radio can confirm overflowing. A thickening of the plèvre can also be noted at this time. If the attending practitionar suspects a cancer, it can address its patient to a consulting hospital specialized in the lung cancer and the mesothelioma. When your doctor recommends to address to you, the following information should be given to you: The place where you are addressed. When the appointment is taken. Who you will consult. With which test can you expect. When the result of the tests is available. The National Institute of Health and Clinical Excellence (National Institute for Health and Clinical Excellence) developed the following general directives to address a suspect patient of cancer, into force since June 2005. These directives can not apply to all the individuals, and you should always discuss the details of your specific case with your team of medical care, so that you can play a function anticipatoire in your treatment and your care. An evaluation of the urgency will be made by your doctor and will be based on the following criteria: To address immediately: The patient requires a consultation in the hours which follow. To address in an urgent way: The patient will be seen in the 15 days which follow. Nonurgent: All other addresses. Once the determined urgency, your doctor will send all the information which concerns with your case with your specialist for evaluation. Diagnosis : A diagnosis of mesothelioma is often obtained starting from a sober estimate of the clinical and radiological conclusions, in more than one tissue biopsy of confirmation. Some of the tests which your specialist can recommend and their diagnostic value and of evaluation of the mesothelioma are presented hereafter. Tomography computer-assisted (CT) the tomodensitométries are able to reveal a pleural overflowing, as well as pleural thickening, pleural calcification, thickening of the interlobular cracks or possible invasion of the thoracic walls. However, the CT cannot make the difference between changes associated with a benign asbestos disease, or between a adenocarcinomist of the lung and a mesothelioma. The tomodensitométries can also have a value to guide the fine needle of aspiration of pleural masses for the tissue diagnosis. This scanner usually takes 10-30 minutes, but can vary according to the patient. Imagery by magnetic resonance (IRM) scanners IRM are often used to determine the width of a tumour before an aggressive treatment. They provide images in multiple plans and peuvnt thus to better identify the tumours compared to the normal structures. They are as more exact as the CT to estimate the widening of the médiastinaux lymphatic ganglia placed between the two lungs, as well as a clear diaphragmatic surface, both having an important function for the surgical option. This scanner IRM takes usually 20-40 minutes, but can vary according to the patient. Tomography by emission of positons (Mtoe) imagery Mtoe is occupying a significant part of the diagnosis and evaluation of the mesothelioma. The Mtoe are regarded as the best diagnostic tumoral sites, as well as best to determine the stage of the mesothelioma. Scanners Mtoe are relatively new and can thus not be available in all the establishments, it can prove to be necessary to travel to find a center specialized which has one of them. The analysis fluid To analyze the pleural liquid to find there cells malignant has only one diagnostic value limited for the mesothelioma. The diagnostic thoracentèse by which cells are extracted from the pleural cavity is made commonly when there is a suspicion of mesothelioma. Unfortunately, the results are negative or not conclusive in almost 85% of the tests. Even in the case of a result of positive liquid, the doctors can choose a biopsy of confirmation since it is not with the detriment of the health of the patient. Analyze fabric (Biopsy) In the majority of the cases, finally a needle takes a biopsy of plèvre, or a surgical biopsy confirms the diagnosis of mesothelioma. At the time of a procedure of pleural biopsy, the surgeon makes a small incision in the thoracic wall and inserts in the chest between two coasts a thin illuminated tube called thorascope. He will withdraw a fabric sample which will be then to examine under microscope by a pathologist. At the time of biopsy péritonéale, the made surgeon of a small incision in the abdomen and insert a péritonéoscope in the abdominal cavity.

The knowledge of the stages of your mesothelioma will be a factor which will make it possible to help your doctor to formulate a plan of treatment. The most final classification and most largely used is the International system of classification TGM for diffuse malignant pleural mesothelioma, also called international Système of the group interested in the mesothelioma (International Mesothelioma Interest Group System). This system takes into account the primary tumour (T), the lymphatic ganglia (G) and metastases (M). There is no system of classification established for the mesothelioma péritonéal. The péritonéaux patients can be classified according to general system TGM for cancer, or on the tumoral load present (C-with-D., imperceptibly bulky, moderately bulky, etc). System TGM is very thorough and difficult to interpret by the laymen, which follows in is a simplified version. Stage I is earliest; The most advanced Stage IV. Stage I the mesothelioma implies the right or left plèvre and can also extend to the lung, the pericardium or the diaphragm on the same side. The ganglia are not implied. Stage II the mesothelioma extends to the plèvre on a side to the lymphatic ganglia close to the lung on the same side. It also could extend to the lung, the pericardium or the diaphragm on the same side. Stage III the mesothelioma invades the thoracic wall, the muscle, the coasts, the heart, the oesophagus or other bodies in the chest on the same side with or without extension to the lymphatic ganglia on the same side as the primary tumour. Stage IV the mesothelioma extends to the lymphatic ganglia in the chest on the side opposed to the primary tumour, or extends to the plèvre or the lung on the opposed side, or extends directly to the bodies from the abdominal cavity or the neck. All distant metastases is included in this stage.

Best the option of treatment for you as an individual, will depend on many factors such as your age, health general, stage of cancer, cellular type (which determines the aggressiveness of cancer) and, most important, your wish personal. In order to help you to evaluate these options, a "team multidisciplinary" (MDT) doctors will discuss your case and will offer their strategy of treatment to you. This team can include a cardio-thoracic surgeon, a medical oncologist, a oncologist radiologist, a specialist in management in the pain and a specialist in palliative care. Nurses and other suppliers of medical care can also be implied in your care. The conventional treatment of the mesothelioma offers several options, and you should discuss à.fond each option with your EMD before making a decision of treatment. Ensure you to have information on the factors of risk, the forecast of the treatment, the side effects potentials and the quality of life which each option offers. Surgery There are two surgical approaches of the mesothelioma, the pleurectomy/hulling (P/D) and the pleuropneumonectomy extrapleurale (PPEP). In fact extremely specialized surgeries, and can not be offered in all the establishments. All the thoracic surgeons are not qualified for these types of surgeries. The ultimate objective of these procedures is the elimination of a large part of the disease, by knowing that most probably the residual microscopic disease will remain. The auxiliary therapy by which additional forms of treatment are used jointly with the primary therapy, typically aims at eliminating the residual disease. The most common forms of therapy auxiliary are the radiotherapy and/or chemotherapy. The pleurectomie/decortication is considered the least radical of the two approaches since it implies only the elimination of the plèvre (coating of the lung) without withdrawing the lung under-jascent. In certain cases, the pericardium and the diaphragm must be withdrawn, according to the width of the tumour. The advantages of this procedure are a time of recovery generally faster, and the utility for the patients who can not be capable to tolerate a more radical PPEP. The disadvantages include/understand an increased risk of recurrence of the disease because of impossibility of withdrawing all the tumour, and impossibility of using high amounts of auxiliary rays because of potential damage to the subjacent lung. The pleuropneumonectomy extrapleurale is a more radical procedure which implies the elimination of the lung, of the plèvre (coating of the lung), of the pericardium which surrounds the heart and a part of the diaphragm. During the surgery, the pericardium and the diaphragm are rebuilt with a material similar to Gortex. To be eligible for this surgery, the patients must satisfy certain criteria of stage and show pulmonary and cardiac functions adequate to be capable to support the procedure.

Chemotherapy implies the use of anti-cancer drugs which act by preventing the cancereuses cells from multiplying. In the majority of the cases, combinations of drugs are used to increase the effectiveness by it. Chemotherapy can be used aggressively to reduce the tumour, or palliativement to relieve of the symptoms like the breathlessness or the pain. Chemotherapy can be managed by injection in a vein or a muscle, by ingestion or can sometimes be managed directly in the pleural cavity or péritonéale. The drugs most commonly used are: Pemetrexed (Alimta) Cisplatine (Platinol) Carboplatine (Paraplatin) Gemcitabine (Gemzar) Doxorubicine (Adriamycin) Mitomycine Raltitrexed (Tomudex) Vinorelbine (Navelbine) Of new drugs are constantly studied by the pharmaceutical firms, thus do not hesitate to inform you near your doctor about the most recent drugs and most promising. Such a drug, Alimta (pemetrexed) was approved for Europe in September 2005.

The radiotherapy implies the use of x-rays of high energy to kill the cancerous cells and to reduce the tumours. It can be used jointly with the surgery to contribute aggressively to remove the microscopic sowing which can cause the recurrence of disease, or palliativement to treat the pain caused by the tumours which compress nervous terminations or another body. The radiotherapy also was effective to prevent sowing tumoral starting from sites of biopsy or tube of drainage of the chest. Clinical trials the goal of the clinical trials is to imply patients in the discovery of new and better treatments for their diseases. Various clinical trials have various objectives which can include the test of new drugs, by comparing several ways of treating a disease or the test of several techniques to prevent cancer. The clinical trials are divided into three phases. Short summaries of what each phase of the test seeks to achieve are described hereafter. The tests of phase I are those of the earliest phase in the system of clinical trials. At this point, the drugs were tested in laboratory only, but had a destroying effect on cancerous cells. These tests enrôlent only one limited number of participants, and are available only in few institutions of cancer. The objective of the tests of Phase I are to determine the tolerated maximum proportioning of the drug without causing serious side effects which side effects are most common, and if the drug continues to have an anti-cancer activity when it is managed with human beings. If the drug shows an effect on cancer with a proportioning without danger, the drug will be then tested in tests of Phase II. The essays of Phase II continue to test the safety of the drugs or the procedures, but also start more attentively to analyze their particular effectiveness for certain types of cancer. These tests include/understand greater numbers of participants, and can be dispersed on several establishments. These tests can "be randomized", i.e. that various groups of participants are chosen by computer, rather than by a doctor. The tests of Phase III compare new promising drugs or procedures with the standard treatment running. Great numbers of participants coming from largely dispersed areas take part in these tests, and receive either the new treatment or the standard treatment. One of the primary education objectives of the tests of Phase III is to determine if cancer is reduced or slowed down by the drugs, how long the patients remain stable without progression of the disease and how the treatment by the drug affects the quality of life of the patient. If you are interested to take part in a clinical trial for the mesothelioma, your doctor should be able to provide you the information on eligibility and the availability in your area.